Source: International Congress 2016 – ILD pathogenesis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Masakiyo Yatomi (Maebashi, Japan), Masakiyo Yatomi, Takeshi Hisada, Yoshimasa Hachisu, Yasuyuki Saito, Hiroaki Tsurumaki, Yosuke Kamide, Haruka Aoki-Saito, Yasuhiko Koga, Akihiro Ono, Kunio Dobashi, Tamotsu Ishizuka, Masanobu Yamada, Fumikazu Okajima. 17(R)-resolvinD1 improves MMP-9/TIMP-1 imbalance leading to amelioration of pulmonary fibrosis in mice. Eur Respir J 2016; 48: Suppl. 60, 3094

Member's Comments

No comment yet.

Related content which might interest you: 17(R)-resolvin D1 attenuates bleomycin-induced lung fibrosis in mice Source: Annual Congress 2013 –Novel in vitro and animal models to study lung diseases Year: 2013 Increased levels of oxidative stress markers in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016 Increased fibrinolytic mediators in IPF as potential contributors to pulmonary fibrosis and vascular remodeling Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Role of midkine in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 The ratio AGE/RAGE is increased in idiopathic pulmonary fibrosis Source: International Congress 2015 – Connective tissue disorders Year: 2015 Novel biomarkers in bleomycin-induced pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 Serum surfactant protein D may predict the effect of pirfenidone in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Aquoaporin-1 expression in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Role of dendritic cells in pulmonary fibrosis in mice Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 Fibulin-1 is a novel biomarker of disease severity in pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Assessment of nutritional status in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – Long-term oxygen therapy, noninvasive ventilation, and other clinical variables in chronic lung diseases Year: 2016 Changes in the small airways in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Treprostinil administration attenuates bleomycin-induced lung fibrosis in mice Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 The immunomodulatory effect of protein S in pulmonary fibrosis Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Serum IGFBP2 as a marker of idiopathic pulmonary fibrosis Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 Club cell secretory protein-CC16 is increased in idiopathic pulmonary fibrosis Source: International Congress 2016 – ILD pathogenesis Year: 2016 Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis Source: Eur Respir Rev, 28 (153) 190022; 10.1183/16000617.0022-2019 Year: 2019